Simcere

Photo of a final puzzle piece about to fit into a puzzle

Biotech

NextCure advances ADC pivot with $745M deal for phase 1 drug

NextCure has ramped up its ADC pivot, penning a $745 million deal for the ex-China rights to Simcere Zaiming’s phase 1-stage tumor asset.

James Waldron Jun 16, 2025 9:52am

AbbVie

JPM25: AbbVie pens $1B deal for Simcere’s ph. 1 T-cell engager

Jan 13, 2025 10:28am

Massachusetts General Hospital

Editas backer Partners taps Lilly to help raise $171M fund

Nov 9, 2017 6:48am